Development of a visualization model for immunological parameters to predict the severity of cardiovascular diseases

Number №4, 2025 — pp. 17-25
DOI: 10.29188/2712-9217-2025-11-4-17-25
For citation: Krylov A.S., Myagkova M.A., Bobrova Z.V., Petrochenko S.N. Development of a visualization model for immunological parameters to predict the severity of cardiovascular diseases. Russian Journal of Telemedicine and E-Health 2025;11(4):17-25; https://doi.org/10.29188/2712-9217-2025-11-4-17-25
Information about authors:
  • Krylov A.S. – Junior Researcher, DIANARK LLC; Moscow, Russia; https://orcid.org0000-0001-7085-3437
  • Myagkova M.A. – Dr. Sci. (Biol.), Professor, Leading Researcher, Institute of Physiologically Active Compounds, Federal Research Center for Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences; Chernogolovka, Moscow Region, Russia; https://orcid.org0000-0001-7831-7663
  • Bobrova Z.V. – Researcher, DIANARK LLC; Moscow, Russia; https://orcid.org0000-0002-8073-8763
  • Petrochenko S.N. – general director DIANARK LLC; Moscow, Russia; https://orcid.org/0000-0003-3656-9007
326

Introduction. This study presents the practical application of a developed software suite designed for the visualization and analysis of immunological parameters in patients with cardiovascular diseases (CVD). The core of the software is an original three-dimensional mathematical balance model that integrates laboratory immunochemical data into an interactive graphical system. Visualization is achieved through dynamic changes in the tilt angle of a virtual platform, reflecting the cumulative state of key immunological parameters associated with CVD pathogenesis.

Materials and methods. We investigated the levels of natural antibodies (n-Abs) to key bioregulators—serotonin, dopamine, histamine, and angiotensin II—in patients with various forms of CVD. The analysis included three groups: 1) patients with arterial hypertension (n=45), 2) patients with combined pathology (hypertension and coronary artery disease, n=53), and 3) a control group (n=41). Antibody levels were determined using ELISA.

Results. A statistically significant increase in n-Ab levels was observed in all patient groups compared to controls, with the most pronounced changes in patients with mixed pathology. A mathematical balance model was proposed to integrate laboratory data and predict CVD severity. The results were validated by clinical assessments of the examined patients.

Conclusions. The developed software features a user-friendly interface, adjustable settings, and a scale for measuring the platform’s tilt angle. This system can be applied in telemedicine for disease progression prediction and clinical decision support.

AttachmentSize
DownloadPDF

The journal contains medical materials intended for healthcare professionals and students of medical educational institutions.